Immunotherapy Market value, page-39

Goetz fair valuation of IMM based on 'SOTP' (sum of the parts) is 0.078. EFTI representing >90% of this valuation.

They also advise that positive data from AIPAC phase 2 trial would increase valuation to 0.110 (very conservative imo if data is good)

Therefore based on other partnerships Goetz places value of IMP 761 at around 5% of SOTP.

I would suggest Altium has a completley different view and financial modelling,having invested $5.2 million, with their primary interest in 761, which is at pre-clinical stage. First data out next week, which is already in the public domain and positive.

Autoimmune disease is a huge market (over $100 billion industry) - 80 different disease types, expensive to treat and treatments have side- effects.

As has been discussed by the seasoned IMM campaigners, IMP 761 may well be the 'jewel in the crown' and whilst its still early days. I now see Altium's rationale and understand the need for additional capital to extend cash runway and further develop 761.